- Home
- IONR vs CMPX Comparison
IONR vs CMPX Comparison
Compare IONR & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONR
- CMPX
- Stock Information
- Founded
- IONR 2001
- CMPX 2014
- Country
- IONR Australia
- CMPX United States
- Employees
- IONR N/A
- CMPX N/A
- Industry
- IONR
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- IONR
- CMPX Health Care
- Exchange
- IONR Nasdaq
- CMPX Nasdaq
- Market Cap
- IONR 319.2M
- CMPX 214.6M
- IPO Year
- IONR N/A
- CMPX N/A
- Fundamental
- Price
- IONR $4.11
- CMPX $2.00
- Analyst Decision
- IONR
- CMPX Strong Buy
- Analyst Count
- IONR 0
- CMPX 4
- Target Price
- IONR N/A
- CMPX $13.75
- AVG Volume (30 Days)
- IONR 25.0K
- CMPX 1.8M
- Earning Date
- IONR 01-01-0001
- CMPX 11-12-2024
- Dividend Yield
- IONR N/A
- CMPX N/A
- EPS Growth
- IONR N/A
- CMPX N/A
- EPS
- IONR N/A
- CMPX N/A
- Revenue
- IONR N/A
- CMPX $850,000.00
- Revenue This Year
- IONR N/A
- CMPX N/A
- Revenue Next Year
- IONR N/A
- CMPX $613.39
- P/E Ratio
- IONR N/A
- CMPX N/A
- Revenue Growth
- IONR N/A
- CMPX N/A
- 52 Week Low
- IONR $2.90
- CMPX $0.77
- 52 Week High
- IONR $9.35
- CMPX $2.68
- Technical
- Relative Strength Index (RSI)
- IONR 42.24
- CMPX 65.48
- Support Level
- IONR $3.71
- CMPX $1.43
- Resistance Level
- IONR $4.58
- CMPX $2.68
- Average True Range (ATR)
- IONR 0.34
- CMPX 0.24
- MACD
- IONR 0.07
- CMPX 0.06
- Stochastic Oscillator
- IONR 51.04
- CMPX 46.87
About IONR ioneer Ltd
Ioneer Ltd is a mineral exploration company. The company's focus is on the Rhyolite Ridge Lithium-Boron Project located in Nevada, USA. Geographically, the group has a business presence in Australia and North America. The company's focus is to develop a U.S.-based source of lithium and boron that can be extracted in an environmentally and socially responsible manner, providing two materials that are essential to achieve a sustainable future for the planet.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.